

**Haemonetics Corporation Financial Summary**  
**(Unaudited data in thousands, except per share data)**

**Consolidated Statements of Income for the First Quarter FY10**

	6/27/09 As Reported	6/28/08 As Reported	% Inc/(Dec) vs Prior Year
<b>NET REVENUES</b>	<u>\$154,087</u>	<u>\$144,116</u>	6.9%
Gross Profit	82,943	73,037	13.6%
R&D	6,777	5,844	16.0%
S,G&A	49,839	47,859	4.1%
Operating Expenses	<u>56,616</u>	<u>53,703</u>	5.4%
Operating Income	26,327	19,334	36.2%
Interest Expense	(214)	(24)	791.7%
Interest Income	157	654	(76.0%)
Other (Expense)/Income, Net	<u>(335)</u>	<u>375</u>	(189.3%)
Income Before Taxes	25,935	20,339	27.5%
Tax Expense	7,862	5,998	31.1%
<b>NET INCOME</b>	<u><u>\$18,073</u></u>	<u><u>\$14,341</u></u>	26.0%
<b>Net Income per Common Share</b>			
<b>Assuming Dilution</b>	\$0.69	\$0.54	27.5%
Weighted Average Number of Shares			
Basic	25,658	25,607	
Diluted	26,201	26,517	
<b>Profit Margins:</b>			Inc/(Dec) vs prior year profit margin %
Gross Profit	53.8%	50.7%	<u>3.1%</u>
R&D	4.4%	4.1%	0.3%
S,G&A	32.3%	33.2%	(0.9%)
Operating Income	17.1%	13.4%	3.7%
Income Before Taxes	16.8%	14.1%	2.7%
Net Income	11.7%	10.0%	1.7%

## Revenue Analysis for the First Quarter FY10

	First Quarter		
	6/27/09 As Reported	6/28/08 As Reported	% Inc/(Dec) vs Prior Year
<b>Revenues by Geography</b>			
United States	\$75,013	\$65,789	14.0%
International	\$79,074	\$78,327	1.0%
Net Revenues	<u>\$154,087</u>	<u>\$144,116</u>	6.9%
<b>Disposable Revenues by Product Family</b>			
Plasma Disposables	\$58,869	\$46,868	25.6%
Blood Bank Disposables			
Platelet	\$34,307	\$35,659	(3.8%)
Red Cell	\$11,779	\$11,842	(0.5%)
	<u>\$46,086</u>	<u>\$47,501</u>	(3.0%)
Hospital Disposables			
Surgical	\$17,425	\$17,269	0.9%
OrthoPAT	\$8,584	\$8,796	(2.4%)
Diagnostics	\$4,997	\$5,094	(1.9%)
	<u>\$31,006</u>	<u>\$31,159</u>	(0.5%)
Subtotal	\$135,961	\$125,528	8.3%
Software Solutions	\$8,454	\$7,258	16.5%
Equipment & Other	\$9,672	\$11,330	(14.6%)
Net Revenues	<u>\$154,087</u>	<u>\$144,116</u>	6.9%

## Consolidated Balance Sheets

	Period ending	
	<u>6/27/09</u>	<u>3/28/09</u>
<b><u>Assets</u></b>		
Cash & Cash Equivalents	\$173,822	\$156,721
Accounts Receivable, Net	114,161	113,598
Inventories, Net	76,097	76,522
Other Current Assets	<u>32,074</u>	<u>35,552</u>
Total Current Assets	396,154	382,393
Net PP&E	150,387	137,807
Other Assets	<u>145,402</u>	<u>129,493</u>
 Total Assets	 <u><u>\$691,943</u></u>	 <u><u>\$649,693</u></u>

	Period ending	
	<u>6/27/09</u>	<u>3/28/09</u>
<b><u>Liabilities &amp; Stockholders' Equity</u></b>		
S/T Debt & Current Maturities	\$17,200	\$695
Other Current Liabilities	<u>86,852</u>	<u>92,168</u>
Total Current Liabilities	104,052	92,863
Long-Term Debt	5,160	5,343
Other Long-Term Liabilities	18,878	11,603
Stockholders' Equity	<u>563,853</u>	<u>539,884</u>
 Total Liabilities & Equity	 <u><u>\$691,943</u></u>	 <u><u>\$649,693</u></u>

## FREE CASH FLOW RECONCILIATION

	Three Months Ended	
	<u>6/27/09</u>	<u>6/28/08</u>
GAAP CASH FLOW FROM OPERATIONS	<u>\$25,706</u>	<u>\$13,842</u>
Capital Expenditures	(21,204)	(12,395)
Proceeds from Sale of Property, Plant and Equipment	<u>201</u>	<u>2,476</u>
Net Investment in Property, Plant and Equipment	<u>(21,003)</u>	<u>(9,919)</u>
Free Cash Flow	<u><u>\$4,703</u></u>	<u><u>\$3,923</u></u>

## **Haemonetics Corporation Financial Summary**

### **Reconciliation of Non-GAAP Measures**

Haemonetics has presented supplemental non-GAAP financial measures as part of this earnings release. A reconciliation is provided below that reconciles each non-GAAP financial measure with the most comparable GAAP measure. The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures. There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.

These measures are used by management to monitor the financial performance of the business, inform business decision making, and forecast future results. Performance targets for management are established based upon these non-GAAP measures. In the reconciliations below, we have removed restructuring costs from our GAAP expenses. These restructuring costs result from a significant transformation of our business during our fiscal years 2009 and 2008. This transformation resulted in the formation of a shared service center in Europe, exiting various offices across Europe and Japan and, most recently, in repositioning our technical operations organization. We believe this information is useful for investors because it allows for an evaluation of the Company with a focus on the performance of our core operations.

#### **Non-GAAP Gross Profit**

The use of these non-GAAP measures allows management to monitor the level of total gross profits without the costs of our business transformation. We establish our budgets, forecasts, and performance targets on this basis.

#### **Non-GAAP S,G&A and Non-GAAP Operating Expenses**

The use of this non-GAAP measure allows management to monitor the ongoing level of spend that is necessary to support the business in a period when we are not transforming our business or completing an acquisition of in-process research and development. We establish our budgets, forecasts, and performance targets excluding these costs.

#### **Non-GAAP Operating Income and Non-GAAP Income before Income Taxes**

The use of these non-GAAP measures allows management to monitor the level of operating and total pre-tax profits without the costs of our business transformation. We establish our budgets, forecasts, and performance targets on this basis.

#### **Non-GAAP Net Income and Earnings per Share**

The use of these non-GAAP measures allows management to monitor the level of net income and earnings per share excluding both the costs of our business transformation, as well as any related tax effects. We establish our budgets, forecasts, and performance targets on this basis.

## Reconciliation of Non-GAAP Measures for the First Quarter of FY10 and FY09

	06/27/09	06/28/08
<b>Non-GAAP Gross Profit</b>		
GAAP Gross Profit	\$82,943	\$73,037
Restructuring Costs	0	72
Non-GAAP Gross Profit	<u>\$82,943</u>	<u>\$73,109</u>
<b>Non-GAAP S,G&amp;A</b>		
GAAP S,G&A	\$49,839	\$47,859
Restructuring Costs	0	(1,781)
Non-GAAP S,G&A	<u>\$49,839</u>	<u>\$46,078</u>
<b>Non-GAAP Operating Expenses</b>		
GAAP Operating Expenses	\$56,616	\$53,703
Restructuring Costs	0	(1,781)
Non-GAAP Operating Expenses	<u>\$56,616</u>	<u>\$51,922</u>
<b>Non-GAAP Operating Income</b>		
GAAP Operating Income	\$26,327	\$19,334
Restructuring Costs	0	1,853
Non-GAAP Operating Income	<u>\$26,327</u>	<u>\$21,187</u>
<b>Non-GAAP Income Before Taxes</b>		
GAAP Income Before Taxes	\$25,935	\$20,339
Restructuring Costs	0	1,853
Non-GAAP Income Before Taxes	<u>\$25,935</u>	<u>\$22,192</u>
<b>Non-GAAP Net Income</b>		
GAAP Net Income	\$18,073	\$14,341
Restructuring Costs	0	1,853
Tax Benefit Associated With Restructuring Costs	0	(650)
Non-GAAP NET INCOME	<u>\$18,073</u>	<u>\$15,544</u>
<b>Non-GAAP Net Income Per Common Share Assuming Dilution</b>		
GAAP Net Income per Common Share Assuming Dilution	\$0.69	\$0.54
Restructuring Costs After Tax per Common Share Assuming Dilution	\$0.00	\$0.05
Non-GAAP Net Income per Common Share Assuming Dilution	<u>\$0.69</u>	<u>\$0.59</u>